alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### WILLIAM H. HACKETT v. TURNER J. STARKS AND ANOTHER.1

December 21, 1923.

No. 23,697.

Denial of temporary injunction a discretionary order.

The order of the trial court denying a temporary injunction against the construction of a building on the property of the defendants within a specified distance of the property line, the plaintiff claiming that an ordinance prohibited the construction within such distance, is sustained as a discretionary one.

Action in the district court for Ramsey county to restrain defendants from erecting a certain building and for a temporary injunction to restrain its construction during the pendency of the action. From an order discharging an order to show cause why a temporary injunction should not issue, Sanborn, J., and from the restraining order, plaintiff appealed.

Affirmed.

*Peder M. Hage,*for appellant.

*George W. Hamilton, Jr.*for respondents.

1

 Reported in 196 N. W. 492.

Dibell, J.

The court denied the application of the plaintiff for a temporary injunction restraining the defendants from building upon certain property within 30 feet of the street line, and he appeals.

*412The application was heard upon the complaint and opposing affidavits. An ordinance of St. Paul, known as No. 5608, requires property owners in residence districts not to build within 30 feet of the property line. It is claimed by the defendants that this ordinance is unconstitutional. Further, they claim that the later zoning ordinance, No. 5840, changes the residential districts fixed by ordinance No. 5608. And in opposition to this view it is the contention of the plaintiff that the effect of section 18 of ordinance No. 5840, which is in some measure an interpretation clause, prevents a construction of the ordinance resulting in a change of residence districts, a contention which is far-reaching indeed.

The record was perhaps such as to require a denial of the injunction; but in any event the court was right in denying -it in the exercise of a proper discretion. The determination of the final question may be important to many. It should not be made on so inexact a record as is before us. The case, before a review establishing a final precedent, should go to hearing on evidence.

Order affirmed.
§ 556.273 Famphur. ( a ) [Reserved]
( b ) *Tolerances.* The tolerance for famphur including its oxygen analog is: ( 1 ) *Cattle.* Edible tissues (excluding milk): 0.1 ppm.
( 2 ) [Reserved]
( c ) *Related conditions of use.* See §§ 520.1242g, 524.900, and 558.254 of this chapter.
# C_2015007EN.01001301.xml

| 12.1.2015 | EN | Official Journal of the European Union | C 7/13 |
| --- | --- | --- | --- |

12.1.2015

EN

Official Journal of the European Union

C 7/13

---

Request for a preliminary ruling from Tribunal Supremo — Sala Tercera Contencioso-Administrativo (Spain) lodged on 14 October 2014 — Entidad de Gestión de Derechos de los Productores Audiovisuales (EGEDA) and Others v Administración del Estado and Others

(Case C-470/14)

(2015/C 007/18)

Language of the case: Spanish

Referring court

Referring court

Tribunal Supremo, Sala Tercera Contencioso-Administrativo

Parties to the main proceedings

Parties to the main proceedings

Applicants: Entidad de Gestión de Derechos de los Productores Audiovisuales (EGEDA), Derechos de Autor de Medios Audiovisuales (DAMA) and Visual Entidad de Gestión de Artistas Plásticos (VEGAP)

Applicants:

Defendants: Administración del Estado, Asociación Multisectorial de Empresas de la Electrónica, las Tecnologías de la Información y la Comunicación, de las Telecomunicaciones y de los contenidos Digitales (AMETIC), Entidad de Gestión, Artistas, Intérpretes o Ejecutantes y Sociedad de Gestión de España (AIE), Asociación de Gestión de Derechos Intelectuales (AGEDI), Sociedad General de Autores y Editores (SGAE), Centro Español de Derechos Reprográficos (CEDRO) and Artistas Intérpretes, Sociedad de Gestión (AISGE)

Defendants:

Questions referred

Questions referred

| 1) | Is a scheme for fair compensation for private copying compatible with Article 5(2)(b) of Directive 2001/29 (1) where the scheme, while taking as a basis an estimate of the harm actually caused, is financed from the General State Budget, it thus not being possible to ensure that the cost of that compensation is borne by the users of private copies? |
| --- | --- |

1)

Is a scheme for fair compensation for private copying compatible with Article 5(2)(b) of Directive 2001/29 (1) where the scheme, while taking as a basis an estimate of the harm actually caused, is financed from the General State Budget, it thus not being possible to ensure that the cost of that compensation is borne by the users of private copies?

1

| 2) | If the first question is answered in the affirmative, is the scheme compatible with Article 5(2)(b) of Directive 2001/29 where the total amount allocated by the General State Budget to fair compensation for private copying, although it is calculated on the basis of the harm actually caused, has to be set within the budgetary limits established for each financial year? |
| --- | --- |

2)

If the first question is answered in the affirmative, is the scheme compatible with Article 5(2)(b) of Directive 2001/29 where the total amount allocated by the General State Budget to fair compensation for private copying, although it is calculated on the basis of the harm actually caused, has to be set within the budgetary limits established for each financial year?

---

(1)  Directive 2001/29/EC of the European Parliament and of the Council of 22 May 2001 on the harmonisation of certain aspects of copyright and related rights in the information society OJ 2001 L 167, p. 10.

1

---
§ 610.41 Donor deferral. ( a ) You, an establishment that collects human blood or blood components, must defer donors testing reactive by a screening test for evidence of infection due to a relevant transfusion-transmitted infection(s) under § 610.40(a), from future donations of human blood and blood components, except: ( 1 ) You are not required to defer a donor who tests reactive for anti-HBc or anti-HTLV, types I and II, on only one occasion. However, you must defer the donor if further testing for HBV or HTLV has been performed under § 610.40(e) and the donor is found to be positive, or if a second, licensed, cleared, or approved screening test for HBV or HTLV has been performed on the same donation under § 610.40(a) and is reactive, or if the donor tests reactive for anti-HBc or anti-HTLV, types I and II, on more than one occasion;
( 2 ) A deferred donor who tests reactive for evidence of infection due to a relevant transfusion-transmitted infection(s) under § 610.40(a) may serve as a donor for blood or blood components shipped or used under § 610.40(h)(2)(ii);
( 3 ) A deferred donor who showed evidence of infection due to hepatitis B surface antigen (HBsAg) when previously tested under § 610.40(a), (b), and (e) subsequently may donate Source Plasma for use in the preparation of Hepatitis B Immune Globulin (Human) provided the current donation tests nonreactive for HBsAg and the donor is otherwise determined to be eligible;
( 4 ) A deferred donor, who otherwise is determined to be eligible for donation and tests reactive for anti-HBc or for evidence of infection due to HTLV, types I and II, may serve as a donor of Source Plasma;
( 5 ) A deferred donor who tests reactive for a relevant transfusion-transmitted infections(s) under § 610.40(a), may serve as an autologous donor under § 610.40(d).
( b ) A deferred donor subsequently may be found to be eligible as a donor of blood or blood components by a requalification method or process found acceptable for such purposes by FDA. Such a donor is considered no longer deferred.
( c ) You must comply with the requirements under §§ 610.46 and 610.47 when a donor tests reactive by a screening test for HIV or HCV required under § 610.40(a) and (b), or when you are aware of other reliable test results or information indicating evidence of HIV or HCV infection.
[66 FR 31164, June 11, 2001, as amended at 72 FR 48798, Aug. 24, 2007; 80 FR 29897, May 22, 2015]
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-29-1996
<PERIOD-END>                               SEP-29-1996
<CASH>                                     (1,212,000)
<SECURITIES>                                 2,003,000
<RECEIVABLES>                                1,972,000
<ALLOWANCES>                                   521,000
<INVENTORY>                                  1,866,000
<CURRENT-ASSETS>                             7,607,000
<PP&E>                                     108,046,000
<DEPRECIATION>                              19,716,000
<TOTAL-ASSETS>                             144,270,000
<CURRENT-LIABILITIES>                       10,292,000
<BONDS>                                      7,154,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       157,000
<OTHER-SE>                                 113,690,000
<TOTAL-LIABILITY-AND-EQUITY>               144,270,000
<SALES>                                     99,969,000
<TOTAL-REVENUES>                           100,382,000
<CGS>                                       31,546,000
<TOTAL-COSTS>                               53,572,000
<OTHER-EXPENSES>                             6,868,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           1,076,000
<INCOME-PRETAX>                              2,387,000
<INCOME-TAX>                                   986,000
<INCOME-CONTINUING>                          1,401,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,401,000
<EPS-PRIMARY>                                     0.09
<EPS-DILUTED>                                     0.09
        

</TABLE>
COURT OF APPEALS FOR THE

FIRST DISTRICT OF TEXAS AT HOUSTON

ORDER

Appellate case name: Jusden A. Kukowski, Jesse David Hartung d/b/a H & H Hauling, Inc 

and H & H Hauling, Inc. v. Bryce G. Burton

Appellate case number: 01-14-00129-CV

Trial court case number: 13CV1174

Trial court: 56th District Court of Galveston County

The Court requests a response from appellee, Bryce Burton, to the Motion for Stay of 

Trial Court Proceedings filed by appellants on March 1, 2014. The response, if any, is due by 

noon on Friday, April 11, 2014.

It is so ORDERED.

Judge’s signature: /s/ Harvey Brown

X Acting individually  Acting for the Court

Date: April 3, 2014
<PAGE>   1
                                                                    EXHIBIT 23.1


                         CONSENT OF INDEPENDENT AUDITORS


        We consent to the reference to our firm under the caption "Experts" and
to the use of our reports dated February 12, 1998, except for Note 2 as to which
the date is April 13, 1998, in the Registration Statement (Form S-1) and related
Prospectus of IVI Publishing, Inc. for the registration of 2,150,000 shares of
its common stock.



                                                    /s/ ERNST & YOUNG LLP

Minneapolis, Minnesota
May 20, 1998
EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CEC Entertainment, Inc. (the Company) on Form 10-Q for the quarter ended September 30, 2007
as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned certifies to his knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods
presented in the Report.
| | --- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



/s/ Richard M. FrankRichard M. FrankChief Executive OfficerNovember 9, 2007


A signed original of this written statement required by Section 906 has been provided to CEC
Entertainment, Inc. and will be retained by CEC Entertainment, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
§ 522.1014 Gamithromycin. ( a ) *Specifications.* Each milliliter (mL) of solution contains 150 milligrams (mg) gamithromycin.
( b ) *Sponsor.* See No. 000010 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.292 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Cattle* — ( i ) *Amount.* Administer 6 mg/kilogram of body weight (2 mL per 110 pounds) one time by subcutaneous injection in the neck.
( ii ) *Indications for use.* For the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica, Pasteurella multocida,* *Histophilus somni,* and *Mycoplasma bovis* in beef and non-lactating dairy cattle; and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with *M. haemolytica* and *P. multocida.*
( iii ) *Limitations.* Cattle intended for human consumption must not be slaughtered within 35 days from the last treatment. Do not use in female dairy cattle 20 months of age or older. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) [Reserved]
[76 FR 57906, Sept. 19, 2011, as amended at 77 FR 26162, May 3, 2012; 84 FR 39184, Aug. 9, 2019]
§ 7.87 Records related to opportunities for presentation of views conducted before report of criminal violation. ( a ) Records related to a section 305 opportunity for presentation of views constitute investigatory records for law enforcement purposes and may include inter- and intra-agency memorandums. ( 1 ) Notwithstanding the rule established in § 20.21 of this chapter, no record related to a section 305 presentation is available for public disclosure until consideration of criminal prosecution has been closed in accordance with paragraph (b) of this section, except as provided in § 20.82 of this chapter. Only very rarely and only under circumstances that demonstrate a compelling public interest will the Commissioner exercise, in accordance with § 20.82 of this chapter, the authorized discretion to disclose records related to a section 305 presentation before the consideration of criminal prosecution is closed.
( 2 ) After consideration of criminal prosecution is closed, the records are available for public disclosure in response to a request under the Freedom of Information Act, except to the extent that the exemptions from disclosure in subpart D of part 20 of this chapter are applicable. No statements obtained through promises of confidentiality shall be available for public disclosure.
( b ) Consideration of criminal prosecution based on a particular section 305 notice of opportunity for presentation of views shall be deemed to be closed within the meaning of this section and § 7.85 when a final decision has been made not to recommend criminal prosecution to a United States attorney based on charges set forth in the notice and considered at the presentation, or when such a recommendation has been finally refused by the United States attorney, or when criminal prosecution has been instituted and the matter and all related appeals have been concluded, or when the statute of limitations has run.
( c ) Before disclosure of any record specifically reflecting consideration of a possible recommendation for criminal prosecution of any individual, all names and other information that would identify an individual whose prosecution was considered but not recommended, or who was not prosecuted, shall be deleted, unless the Commissioner concludes that there is a compelling public interest in the disclosure of the names.
( d ) Names and other information that would identify a Food and Drug Administration employee shall be deleted from records related to a section 305 presentation of views before public disclosure only under § 20.32 of this chapter.
[44 FR 12168, Mar. 6, 1979]
§ 522.1962 Promazine. ( a ) *Specifications.* Each milliliter of solution contains 50 milligrams (mg) promazine hydrochloride.
( b ) *Sponsors.* See sponsors in § 510.600(c) of this chapter for use as in paragraph (c) of this section: ( 1 ) No. 054771 for use as in paragraphs (c)(1)(i)(A), (c)(1)(ii)(A), (c)(1)(iii), and (c)(2) of this section.
( 2 ) No. 061133 for use as in paragraphs (c)(1)(i)(B), (c)(1)(ii)(B), and (c)(1)(iii) of this section.
( c ) *Conditions of use* — ( 1 ) *Horses* — ( i ) *Amount.* (A) 0.2 to 0.5 milligrams per pounds (mg/lb) body weight intramuscularly or intravenously every 4 to 6 hours. ( B ) 0.2 to 0.5 mg/lb body weight intravenously as required.
( ii ) *Indications for use.* ( A ) For use as a tranquilizer, preanesthetic, or for minor operative procedures in conjunction with local anesthesia; and as adjunctive therapy for tetanus.
( B ) For use as a tranquilizer and preanesthetic.
( iii ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Dogs and cats* — ( i ) *Amount.* 1 to 2 mg/lb body weight intramuscularly or intravenously every 4 to 6 hours.
( ii ) *Indications for use.* For use as a tranquilizer, preanesthetic, for minor operative procedures in conjunction with local anesthesia, as adjunctive therapy for tetanus, and as an antiemetic prior to worming; or to prevent motion sickness in dogs.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[46 FR 18962, Mar. 27, 1981, as amended at 68 FR 59881, Oct. 20, 2003; 70 FR 50183, Aug. 26, 2005; 79 FR 16194, Mar. 25, 2014; 84 FR 8974, Mar. 13, 2019]
§ 582.3640 Potassium sorbate. ( a ) *Product.* Potassium sorbate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SHCEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM GULFWEST OIL
COMPANY'S QUARTERLY REPORT FILED ON FORM 10-Q FOR THE QUARTER ENDED JUNE-30-97
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<CIK>                         0000813779
<NAME>                        0
<MULTIPLIER>                  1
<CURRENCY>                    0
       
<S>                           <C>
<PERIOD-TYPE>                 6-MOS 
<FISCAL-YEAR-END>             DEC-31-1996
<PERIOD-START>                APR-1-1997
<PERIOD-END>                  JUN-30-1997
<EXCHANGE-RATE>               1
<CASH>                        251,944
<SECURITIES>                  0
<RECEIVABLES>                 671,312
<ALLOWANCES>                  0
<INVENTORY>                   0
<CURRENT-ASSETS>              1,090,975
<PP&E>                        17,217,286
<DEPRECIATION>                (1,801,193)
<TOTAL-ASSETS>                16,529,435
<CURRENT-LIABILITIES>         3,999,495
<BONDS>                       0
<PREFERRED-MANDATORY>         0
<PREFERRED>                   51
<COMMON>                      1,753
<OTHER-SE>                    3,610,089
<TOTAL-LIABILITY-AND-EQUITY>  16,529,435
<SALES>                       2,210,623
<TOTAL-REVENUES>              2,900,057
<CGS>                         0
<TOTAL-COSTS>                 2,570,227
<OTHER-EXPENSES>              0
<LOSS-PROVISION>              0
<INTEREST-EXPENSE>            (500,008)
<INCOME-PRETAX>               (152,786)
<INCOME-TAX>                  0
<INCOME-CONTINUING>           (152,786)
<DISCONTINUED>                0
<EXTRAORDINARY>               0
<CHANGES>                     0
<NET-INCOME>                  (152,786)
<EPS-PRIMARY>                 (.09)
<EPS-DILUTED>                 (.09)
        


</TABLE>
I 

118TH CONGRESS 

2D SESSION H. R. 7593 

To enhance the authority of the Director of the Congressional Research 

Service to obtain information directly from agencies of the Federal government. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 8, 2024 

Mrs. BICE (for herself, Mr. CAREY, Mr. KILMER, and Mr. MORELLE) introduced the following bill; which was referred to the Committee on House 

Administration 

A BILL 

To enhance the authority of the Director of the Congressional Research Service to obtain information directly 

from agencies of the Federal government. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Modernizing the Con5 gressional Research Service’s Access to Data Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7593 IH

1 SEC. 2. ACCESS OF CONGRESSIONAL RESEARCH SERVICE 

2 TO GOVERNMENT INFORMATION. 

3 (a) DIRECT ACCESS TO INFORMATION.—Section 203 

4 of the Legislative Reorganization Act of 1946 (2 U.S.C. 

5 166) is amended— 

6 (1) by redesignating subsection (j) as sub7 section (k); and 

8 (2) by inserting after subsection (i) the fol9 lowing new subsection: 

10 ‘‘(j)(1) In carrying out the duties and functions of 

11 the Congressional Research Service under subsection (d), 

12 the Director is authorized to secure books, records, cor13 respondence, memoranda, papers, documents, secure in14 formation, and other data in all forms directly from the 

15 various departments, agencies, and establishments of the 

16 executive branch of the Government and the regulatory 

17 agencies and commissions of the Government as the Direc18 tor determines to be necessary to carry out the request, 

19 and all such departments, agencies, establishments, and 

20 regulatory agencies and commissions shall furnish the Di21 rector with all such available material in a timely manner. 

22 ‘‘(2) With respect to books, records, correspondence, 

23 memoranda, papers, documents, secure information, and 

24 other data in all forms obtained under paragraph (1), the 

25 Director shall maintain the same level of confidentiality 

26 as is required by law of the department, agency, establishVerDate Sep 11 2014 16:00 Mar 17, 2024 Jkt 049200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H7593.IH H7593

ssavage on LAPJG3WLY3PROD with BILLS
3 

•HR 7593 IH

1 ment, or regulatory agency or commission from which it 

2 is obtained. Officers and employees of the Congressional 

3 Research Service shall be subject to the same statutory 

4 penalties for unauthorized disclosure or use as officers or 

5 employees of the department, agency, establishment, or 

6 regulatory agency or commission from which it is ob7 tained.’’. 

8 (b) CONFORMING AMENDMENT.—Section 203(d)(1) 

9 of such Act (2 U.S.C. 166(d)(1)) is amended in the matter 

10 following subparagraph (C) by striking ‘‘and in the per11 formance of this duty’’ and all that follows through ‘‘com12 ply with such request;’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS